Novel cell surface marker

The term "Novel cell surface marker" does not refer to a specific biological molecule, receptor, or therapeutic target. Instead, it is a generic descriptive phrase frequently used in scientific literature to denote a newly identified protein or antigen located on the plasma membrane of a cell, typically in the context of oncology, immunology, or stem cell research [1, 2, 3]. Because it lacks a unique molecular identity or canonical sequence, it cannot be classified within a specific molecular family or associated with a defined mechanism of action for drugs. Numerous distinct proteins, such as Mesothelin (MSLN) in acute myeloid leukemia [2, 8], EPHA2 in pluripotent stem cells [7, 9], and GPRC5D in multiple myeloma [35], have been described as "novel cell surface markers" in various high-profile studies. Consequently, this entry is considered incorrect as a specific target name for drug development or biotech analysis.

N/A